Ameritas Investment Partners Inc. Has $3.13 Million Position in Exelixis, Inc. $EXEL

Ameritas Investment Partners Inc. lessened its position in Exelixis, Inc. (NASDAQ:EXEL) by 2.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 70,949 shares of the biotechnology company’s stock after selling 2,119 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in Exelixis were worth $3,127,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Fuller & Thaler Asset Management Inc. grew its stake in shares of Exelixis by 2.2% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock worth $287,794,000 after acquiring an additional 164,134 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Exelixis by 0.4% during the second quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock worth $328,196,000 after purchasing an additional 28,289 shares during the last quarter. AQR Capital Management LLC grew its position in Exelixis by 73.8% in the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock valued at $250,869,000 after purchasing an additional 2,926,884 shares in the last quarter. Invesco Ltd. grew its position in Exelixis by 40.2% in the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock valued at $205,725,000 after purchasing an additional 1,596,948 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in Exelixis in the 1st quarter valued at $123,310,000. Institutional investors own 85.27% of the company’s stock.

Insider Activity at Exelixis

In related news, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the completion of the sale, the director directly owned 1,189,228 shares of the company’s stock, valued at approximately $51,790,879.40. This trade represents a 7.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total value of $1,032,400.46. Following the completion of the sale, the director owned 21,380 shares of the company’s stock, valued at $896,463.40. This trade represents a 53.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 245,235 shares of company stock valued at $10,490,600. 2.82% of the stock is currently owned by insiders.

Exelixis Price Performance

EXEL stock opened at $42.25 on Tuesday. Exelixis, Inc. has a one year low of $31.90 and a one year high of $49.62. The stock has a market cap of $11.33 billion, a price-to-earnings ratio of 20.31, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32. The company has a fifty day moving average price of $39.93 and a two-hundred day moving average price of $40.73.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million for the quarter, compared to analyst estimates of $590.04 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company’s revenue was up 10.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.47 earnings per share. Exelixis has set its FY 2025 guidance at EPS. Research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Exelixis in a research note on Tuesday, November 18th. They set a “peer perform” rating for the company. Morgan Stanley upped their target price on Exelixis from $44.00 to $45.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. HC Wainwright raised their price target on Exelixis from $46.00 to $49.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Zacks Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. Finally, JMP Securities reiterated a “market outperform” rating and set a $50.00 price objective on shares of Exelixis in a research note on Tuesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and a consensus price target of $45.45.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.